Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro® Enables Discovery and Cryo‑EM Epitope Mapping of CXCR4 Antibodies
2026-04-23
We’re excited to share a recent update from our collaboration with Bio‑Rad and ATEM, advancing antibody discovery for the challenging GPCR target CXCR4.
Using Salipro®‑CXCR4 (wildtype) to stabilize the receptor in a native‑like lipid environment, Bio‑Rad’s Pioneer™ Antibody Discovery Platform generated a diverse panel of high‑affinity CXCR4 antibodies. Several outperformed the benchmark antibody ulocuplumab (BMS) in affinity, functionality, and developability.
Together with ATEM, we advanced this work to cryo‑EM epitope mapping, revealing distinct antibody epitopes on CXCR4 as visualized in the GIF here. This structural insight is key for understanding mechanism of action, differentiating candidates, and enabling clearly defined, defensible IP through novel epitope claims.
Salipro® enables a seamless, end‑to‑end workflow for antibody discovery against difficult membrane protein targets, from native-state stabilization, to antibody discovery, to high‑resolution structural insight.
We thank the teams at Bio‑Rad and ATEM for our excellent collaboration.
Salipro Biotech is heading to Swiss Biotech Day 2026!
2026-04-14
We are participating in Swiss Biotech Day, taking place in Basel from May 4-5 where our Business Development Manager, Lorena Galán Acosta, will be attending in person.
We look forward to connecting with current and future partners in Switzerland to discuss how the Salipro® platform can unlock drug discovery for complex membrane protein targets, including GPCRs, ion channels, and transporters.
If you’d like to meet in Basel, feel free to reach out via the partnering platform to schedule a meeting. Let’s discuss how the Salipro® platform can drive the development of next-generation therapeutics!
Multi-Target Collaboration Agreement with Global Top 5 Pharma Company
2026-04-02
Salipro has entered into a multi-target collaboration agreement with a global Top 5 pharmaceutical company in the USA.
This partnership leverages Salipro Biotech’s expertise and proprietary technology (Salipro®) to stabilise challenging drug targets including GPCRs, ion channels and transporters, making them accessible for the development of next-generation therapeutics.
Stay tuned for more updates as we continue to push the boundaries of drug discovery!